Cepheid Expects to Report Q3 Revenues Below Target | GenomeWeb

NEW YORK (GenomeWeb News) – Cepheid said after the close of the market Wednesday that it expects to report third-quarter revenues of between $79 million and $81 million, below its own target range and Wall Street's average estimate of $83.8 million.

The Sunnyvale, Calif.-based firm said the shortfall is due to "intermittent interruptions in the supply of Xpert cartridge parts." The Xpert cartridges contain the tests that run on the firm's GeneXpert systems.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.